{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:43Z","timestamp":1787010163298,"version":"build-2736575974"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"40","license":[{"start":{"date-parts":[[2022,10,7]],"date-time":"2022-10-07T00:00:00Z","timestamp":1665100800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10,7]]},"abstract":"<jats:sec>\n                    <jats:title>Rationale:<\/jats:title>\n                    <jats:p>The echinoderm microtubule-associated protein-like 4 gene and anaplastic lymphoma kinase gene (EML4-ALK) is the most frequent fusion variant of ALK rearrangements in non-small cell lung cancer (NSCLC). With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations of EML4-ALK have been discovered. Complex co-mutation of EML4-ALK fusions together with BRAF V600E, though rarely occurred, also deserves attention to determine the standard of caring these patients. Herein, we report a case of lung adenocarcinoma harboring a complex ALK fusion that coexisted with a BRAF mutation, as tested by DNA-NGS prior to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patient concerns:<\/jats:title>\n                    <jats:p>A 51-year-old non-smoking man, without any symptoms, was admitted to hospital due to small pulmonary nodules and enlarged supraclavicu larlymph nodes found in health checkup.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Diagnosis:<\/jats:title>\n                    <jats:p>He was diagnosed with stage IVB (T4N3M1c) lung adenocarcinoma. BRAF V600E (abundance 3.75%) mutation and a novel thus little-understood EML4-ALK (E13, A5; abundance 2.16%) fusion were identified by DNA-NGS analysis of lymph node biopsy tissue in December 2019.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Interventions:<\/jats:title>\n                    <jats:p>Darafenib plus trametinib targeted therapy and chemotherapy were given firstly, but tumor progression was not inhibited. The ALK inhibitor alectinib was prescribed then.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcomes:<\/jats:title>\n                    <jats:p>The patient exhibited a rapid disease response to ALK tyrosine kinase inhibitors alectinib with a complete remission of widespread metastatic disease and progression-free survival of more than 26 months, but not to darafenib plus trametinib targeted BRAF V600E therapy. Re-analyzed the patient\u2019s DNA-NGS original data, showed it is a rare and complex EML4-ALK (E13, A5, A20) fusion in fact. Additional RNA-NGS analysis showed it verified to be a canonical EML4-ALK (E13, A20) fusion transcript and coexisting with a BRAF V600E mutation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Lessons:<\/jats:title>\n                    <jats:p>This case suggests that for patients with rare or complex EML4-ALK fusions at DNA level, additional RNA-NGS is necessary to verify its functionality as early as possible. Targeting EML4-ALK firstly may be more preferable despite the coexisting of BRAF V600E.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000030913","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T10:54:50Z","timestamp":1665399290000},"page":"e30913","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Lung adenocarcinoma harboring complex EML4-ALK fusion and BRAF V600E co-mutation responded to alectinib"],"prefix":"10.1097","volume":"101","author":[{"given":"Weihong","family":"Guo","sequence":"first","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Liang","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Zhang","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xikun","family":"Huang","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Lv","sequence":"additional","affiliation":[{"name":"Zhongshan City People\u2019s Hostipial, Zhongshan, Guangdong Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2217\/fon-2021-0945","article-title":"The impact of the ALK fusion variant on clinical outcomes in EML4-ALK patients with NSCLC: a systematic review and meta-analysis.","volume":"18","author":"Wang","year":"2022","journal-title":"Future Oncol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(21)00312-3","article-title":"Lung cancer.","volume":"398","author":"Hai","year":"2021","journal-title":"Lancet"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1097\/JTO.0b013e3182598af3","article-title":"A novel EML4-ALK variant: exon 6 of EML4 fused to exon 19 of ALK.","volume":"7","author":"Penzel","year":"2012","journal-title":"J Thorac Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"4992","DOI":"10.21037\/jtd.2019.12.25","article-title":"Comparison of next-generation sequencing and immunohistochemistry analysis for targeted therapy-related genomic status in lung cancer patients.","volume":"11","author":"Nong","year":"2019","journal-title":"J Thorac Dis"},{"key":"R6-20250504","first-page":"e100015","article-title":"Catalog of 5\u2019 fusion partners in ALK-positive NSCLC Circa 2020.","volume":"19","author":"Ou","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2","DOI":"10.6004\/jnccn.2021.7077","article-title":"A case of lung adenocarcinoma response to Alectinib Harboring a rare EML4-ALK variant, Exon 6 of EML4 fused to Exon 18 of ALK.","volume":"20","author":"Liu","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.lungcan.2021.07.020","article-title":"Identification of a EML4-ALK exon 19 fusion variant in lung adenocarcinoma and alectinib resistance.","volume":"160","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s12967-021-02982-4","article-title":"Molecular characteristics and clinical outcomes of complex ALK rearrangements identified by next-generation sequencing in non-small cell lung cancers.","volume":"19","author":"Xia","year":"2021","journal-title":"J Transl Med"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jtho.2020.10.156","article-title":"Potential unreliability of uncommon ALK, ROS1, and RET genomic Breakpoints in predicting the efficacy of targeted therapy in NSCLC.","volume":"16","author":"Li","year":"2021","journal-title":"J Thorac Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/s41467-019-09374-9","article-title":"Diagnosis of fusion genes using targeted RNA sequencing.","volume":"10","author":"Heyer","year":"2019","journal-title":"Nat Commun"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"4712","DOI":"10.1158\/1078-0432.CCR-19-0225","article-title":"High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden.","volume":"25","author":"Benayed","year":"2019","journal-title":"Clin Cancer Res"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non-small cell lung cancer, version 2.2021.","volume":"19","author":"Ettinger","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"e24917","DOI":"10.1097\/MD.0000000000024917","article-title":"BRAF V600E mutation as a novel mechanism of acquired resistance to ALK inhibition in ALK-rearranged lung adenocarcinoma: a case report.","volume":"100","author":"Sui","year":"2021","journal-title":"Medicine (Baltim)"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.lungcan.2020.05.018","article-title":"BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer.","volume":"146","author":"Shi","year":"2020","journal-title":"Lung Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.lungcan.2013.02.002","article-title":"A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.","volume":"80","author":"Alrifai","year":"2013","journal-title":"Lung Cancer"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer.","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1634\/theoncologist.2017-0642","article-title":"FDA approval summary: dabrafenib and trametinib for the treatment of metastatic non-small cell lung cancers harboring BRAF V600E mutations.","volume":"23","author":"Odogwu","year":"2018","journal-title":"Oncologist"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/S1470-2045(17)30679-4","article-title":"Dabrafenib plus trametinib in patients with previously untreated BRAFV600E-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial.","volume":"18","author":"Planchard","year":"2017","journal-title":"Lancet Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030913","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:40:01Z","timestamp":1746319201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000030913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,7]]},"references-count":19,"journal-issue":{"issue":"40","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000030913","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,7]]}}}